Evidence map›Paper›PMID 31760445›Full record

ArticleAnalytical and bioanalytical chemistry2019

Simultaneous detection and quantification of DNA and protein biomarkers in spectrum of cardiovascular diseases in a microfluidic microbead chip.

Franziska Dinter, Michał Burdukiewicz, Peter Schierack, Werner Lehmann, Jörg Nestler, Gregory Dame, Stefan Rödiger

Open access · hybridAbstract read
In one paragraph

Article in Analytical and bioanalytical chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 38 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Franziska DinterBrandenburg University of Technology Cottbus-Senftenberg, Universitätsplatz 1, 01968, Senftenberg, Germany.
Michał BurdukiewiczFaculty of Mathematics and Informations Science, Warsaw University of Technology, plac Politechniki 1, 00-661, Warsaw, Poland.
Peter SchierackBrandenburg University of Technology Cottbus-Senftenberg, Universitätsplatz 1, 01968, Senftenberg, Germany.
Werner Lehmannattomol GmbH, Schulweg 6, 03205, Bronkow, Germany.
Jörg NestlerBiFlow Systems GmbH, Technologie-Campus 1, 09126, Chemnitz, Germany.
Gregory DameInstitute of Microbiology and Virology-Brandenburg Medical School Theodor Fontane, Universitätsplatz 1, 01968, Senftenberg, Germany.
Stefan RödigerBrandenburg University of Technology Cottbus-Senftenberg, Universitätsplatz 1, 01968, Senftenberg, Germany. stefan.roediger@b-tu.de.ORCID https://orcid.org/0000-0002-1441-6512
Brandenburg University of Technology Cottbus-Senftenberg · DEMedizinische Hochschule Brandenburg Theodor Fontane · DEWarsaw University of Technology · PL

Funding

Ministerium für Wissenschaft, Forschung und Kultur 06-GeCa:H228-05/002/004
6 · The paper itself

Abstract

The rapid and simultaneous detection of DNA and protein biomarkers is necessary to detect the outbreak of a disease or to monitor a disease. For example, cardiovascular diseases are a major cause of adult mortality worldwide. We have developed a rapidly adaptable platform to assess biomarkers using a microfluidic technology. Our model mimics autoantibodies against three proteins, C-reactive protein (CRP), brain natriuretic peptide (BNP), and low-density lipoprotein (LDL). Cell-free mitochondrial DNA (cfmDNA) and DNA controls are detected via fluorescence probes. The biomarkers are covalently bound on the surface of size- (11-15 μm) and dual-color encoded microbeads and immobilized as planar layer in a microfluidic chip flow cell. Binding events of target molecules were analyzed by fluorescence measurements with a fully automatized fluorescence microscope (end-point and real-time) developed in house. The model system was optimized for buffers and immobilization strategies of the microbeads to enable the simultaneous detection of protein and DNA biomarkers. All prime target molecules (anti-CRP, anti-BNP, anti-LDL, cfmDNA) and the controls were successfully detected both in independent reactions and simultaneously. In addition, the biomarkers could also be detected in spiked human serum in a similar way as in the optimized buffer system. The detection limit specified by the manufacturer is reduced by at least a factor of five for each biomarker as a result of the antibody detection and kinetic experiments indicate that nearly 50 % of the fluorescence intensity is achieved within 7 min. For rapid data inspection, we have developed the open source software digilogger, which can be applied for data evaluation and visualization. Graphical abstract.

Indexed as

Lab-On-A-Chip DevicesAutoantibodiesBiomarkersCardiovascular DiseasesCell-Free Nucleic AcidsFluorescent DyesHumansLimit of DetectionMicrospheresProteinsAutoantibodiesBiomarkersCell-Free Nucleic AcidsFluorescent DyesProteinsAutoantibodiesBiomarkerCardiovascular diseaseMicrobeadsMicrofluidicMultiplex

Identifiers

PMID31760445
PMCPMC6881413
OpenAlexW2989661074

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.